Natera launches Alliance A032103 utilizing Signatera MRD test for MIUC

Natera announced the launch of Alliance A032103 MODERN , a randomized, phase II/III, biomarker-integrated trial. Alliance A032103 MODERN will utilize Signatera , Natera’s personalized and tumor-informed molecular residual disease MRD test, to help guide personalized treatment based on molecular status in patients diagnosed with muscle-invasive urothelial cancer MIUC after radical cystectomy. “The MODERN trial represents a step towards precision medicine in bladder cancer treatment,” said Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute. “By using Signatera to measure residual cancer after surgery, the Alliance A032103 (MODERN) trial may ultimately help to tailor the use of immunotherapy after surgery and optimize the care of individual patients.” “MODERN, like the CIRCULATE clinical trials in colorectal cancer, is a pivotal study that examines how Signatera-guided escalation and de-escalation pathways can potentially improve patient outcomes,” said Minetta Liu, MD, chief medical officer of oncology at Natera. “We are grateful to collaborate with the Alliance on this important study.”